Bupropion as a modulator of drug activity
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1. A dosage form comprising:
about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form; and
about 40 mg to about 60 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form; and
wherein the dextromethorphan and the bupropion are substantially uniformly dispersed within the dosage form.
2. The dosage form of claim 1 , comprising about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide.
3. The dosage form of claim 1 , wherein the bupropion is formulated for sustained release.
4. A method of systemically delivering bupropion and dextromethorphan, comprising administering the dosage form of claim 1 to a human being.
5. The method of claim 4 , wherein the dosage form is administered orally.
6. The method of claim 4 , wherein the dosage form is administered once daily.
7. The method of claim 4 , wherein the dosage form is administered twice daily.
8. The method of claim 4 , wherein the dosage form is administered to the human being for at least 8 consecutive days.
9. The method of claim 4 , wherein the dosage form is administered to the human being for at least 14 consecutive days.
10. The method of claim 4 , wherein the dosage form is administered to the human being for at least 30 consecutive days.
11. A dosage form comprising:
about 200 mg to about 220 mg of bupropion hydrochloride, or a molar equivalent amount of a bupropion in the free base form or another salt form; and
about 80 mg to about 100 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a dextromethorphan in the free base form or another salt form; and
wherein the dextromethorphan and the bupropion are substantially uniformly dispersed within the dosage form.
12. The dosage form of claim 11 , comprising about 210 mg of bupropion hydrochloride and about 90 mg of dextromethorphan hydrobromide.
13. The dosage form of claim 11 , wherein the bupropion is formulated for sustained release.
14. A method of systemically delivering bupropion and dextromethorphan, comprising administering the dosage form of claim 11 to a human being.
15. The method of claim 14 , wherein the dosage form is administered orally.
16. The method of claim 14 , wherein the dosage form is administered once daily.
17. The method of claim 14 , wherein the dosage form is administered to the human being for at least 8 consecutive days.
18. The method of claim 14 , wherein the dosage form is administered to the human being for at least 14 consecutive days.
19. The method of claim 14 , wherein the dosage form is administered to the human being for at least 30 consecutive days.